Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

Summary

This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis

Timeline

Start

2017-05-10

Primary completion

2018-06-20

Completion

2018-06-20

Drugs

Indications